AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15865225 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN 1.5 microg/kg/week (arm B)
Number of subjects: 135
Study 11529975 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented care
Number of subjects: 0
Study 9634050 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium treatment (200 microg daily)
Number of subjects: 974
Study 9634050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 974
Study 8141220 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent breast-feeding (nursed 9 times per day)
Number of subjects: 275
Study 8141220 — intervention group
Group type: COMPARATOR
Intervention: Demand breast-feeding (nursed 6.5 times per day)
Number of subjects: 275
Study 3255915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortenoxicam
Number of subjects: 0
Study 30268133 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 996
Study 30268133 — intervention group
Group type: COMPARATOR
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 996
Study 26581111 — intervention group
Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in Study 001
Number of subjects: 76
Study 26581111 — intervention group
Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in Study 101
Number of subjects: 76
Study 26581111 — intervention group
Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in both studies
Number of subjects: 76
Study 25332324 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snack made from green leafy vegetables, fruit, and milk (treatment group)
Number of subjects: 1962
Study 25332324 — intervention group
Group type: COMPARATOR
Intervention: Low-micronutrient vegetables (potato and onion) (control group)
Number of subjects: 1962
Study 22954865 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Representations of the Self (VRS)
Number of subjects: 0
Study 19558381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevent Injury Enhance Performance (PEP) program
Number of subjects: 0
Study 19558381 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 0
Study 19558381 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PEP and CON)
Number of subjects: 0
Study 17660154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg albuterol
Number of subjects: 349
Study 17660154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.62 mg albuterol
Number of subjects: 349
Study 17660154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 15855335 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine (Cu(II)‐selective chelator)
Number of subjects: 0
Study 15855335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 11865828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 200
Study 11865828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9498539 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic regimens
Number of subjects: 247
Study 9498539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical predictors
Number of subjects: 247
Study 9498539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model predictors
Number of subjects: 247
Study 9098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative application of 0.2 mg/ml mitomycin C for 3 minutes
Number of subjects: 227
Study 9098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative application of 0.4 mg/ml mitomycin C for 3 minutes
Number of subjects: 227
Study 9098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C eye drops 0.2 mg/ml three times daily for 7 days
Number of subjects: 227
Study 9098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C eye drops 0.4 mg/ml three times daily for 14 days
Number of subjects: 227
Study 9098301 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 227
Study 2713212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.07 mg kg‐1 min‐1
Number of subjects: 8
Study 2713212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.03 mg kg‐1 min‐1
Number of subjects: 8
Study 2713212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.005 mg kg‐1 min‐1
Number of subjects: 8
Study 946338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (2 mg initially, then 1 mg/day)
Number of subjects: 8
Study 946338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusaric acid (600 mg/day)
Number of subjects: 8
Study 946338 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 946338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide and Fusaric acid
Number of subjects: 8
Study 29956374 — intervention group
Group type: EXPERIMENTAL
Intervention: Public perception of river fish biodiversity
Number of subjects: 4000
Study 29956374 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for conservation measures
Number of subjects: 4000
Study 29956374 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of threats to biodiversity
Number of subjects: 4000
Study 29956374 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservation messaging effectiveness
Number of subjects: 4000
Study 30169244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily until 32 weeks and 0 days' gestation or delivery
Number of subjects: 135
Study 30169244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 30169244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 135
Study 27829464 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS) technique
Number of subjects: 62
Study 27829464 — intervention group
Group type: COMPARATOR
Intervention: Linear incision technique with soft tissue preservation
Number of subjects: 62
Study 24513094 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with timolol 0.5%
Number of subjects: 127
Study 24513094 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with brimonidine 0.2%
Number of subjects: 127
Study 22452789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion after a 4-day high sodium diet (300 mmol sodium/day)
Number of subjects: 41
Study 22452789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion after a 4-day low sodium diet (30 mmol sodium/day)
Number of subjects: 41
Study 22452789 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 41
Study 22452789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during high sodium intake
Number of subjects: 41
Study 22452789 — intervention group
Group type: COMPARATOR
Intervention: Baseline and post-saline measurements of u-PGE2, u-cAMP, AVP, PRC, Ang II, Aldo, ANP, and BNP
Number of subjects: 41
Study 19281321 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular muscle exercises (Paula method)
Number of subjects: 245
Study 19281321 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 245
Study 17189794 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin eyedrops (4 subgroups)
Number of subjects: 193
Study 17189794 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin eyedrops (4 subgroups)
Number of subjects: 193
Study 17189794 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (wick method)
Number of subjects: 193
Study 17189794 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin and Moxifloxacin (comparison)
Number of subjects: 193
Study 16080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg qd)
Number of subjects: 44
Study 16080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg bid)
Number of subjects: 44
Study 16080835 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 44
Study 16080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (both bisoprolol and carvedilol)
Number of subjects: 44
Study 12228887 — intervention group
Group type: EXPERIMENTAL
Intervention: New weighted goodness-of-fit tests
Number of subjects: 0
Study 12228887 — intervention group
Group type: COMPARATOR
Intervention: Hosmer-Lemeshow decile-of-risk test
Number of subjects: 0
Study 12228887 — intervention group
Group type: COMPARATOR
Intervention: Pearson chi-square test
Number of subjects: 0
Study 12228887 — intervention group
Group type: COMPARATOR
Intervention: Unweighted sum-of-squares tests
Number of subjects: 0
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine (450 mg daily p.o. until progression)
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2/daily i.v. weekly for 4 weeks and then every 2 weeks until progression)
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine + vindesine (at the same dose and schedule)
Number of subjects: 126
Study 10426128 — intervention group
Group type: COMPARATOR
Intervention: supportive therapy only
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine + vindesine
Number of subjects: 126
Study 10426128 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine or vindesine
Number of subjects: 126
Study 7493300 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a (IFN-alpha 2a) starting dose 6 MU, adjusted based on ALT response
Number of subjects: 67
Study 7493300 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 67
Study 7493300 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 67
Study 2178643 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group with endotracheal tube introducer
Number of subjects: 40
Study 2178643 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard intubation techniques
Number of subjects: 40
Study 499287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 0
Study 499287 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0
Study 499287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31753866 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (3 weekly sessions of 35 min moderate intensity walking/running and 25 min resistance training until delivery)
Number of subjects: 91
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 12 mg
Number of subjects: 50
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 18 mg
Number of subjects: 50
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 24 mg
Number of subjects: 50
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (all doses)
Number of subjects: 50
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (doses 18 mg and 24 mg)
Number of subjects: 50
Study 27759898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (in patients >110 kg)
Number of subjects: 50
Study 26423650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg twice daily
Number of subjects: 254
Study 26423650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg twice daily
Number of subjects: 254
Study 26423650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg once daily
Number of subjects: 254
Study 26423650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg once daily
Number of subjects: 254
Study 26423650 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 254
Study 26423650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-663068 groups
Number of subjects: 254
Study 23507186 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 30
Study 21123763 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 23
Study 21123763 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 23
Study 19418213 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRM2 genetic variation (marker rs8191992 and additional SNPs)
Number of subjects: 4350
Study 19418213 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 29 SNPs in CHRM2 (Australian sample) and 7 SNPs in English cohort
Number of subjects: 4350
Study 17413836 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 36
Study 17413836 — intervention group
Group type: COMPARATOR
Intervention: Ethoxy‐diaminoacridine plus nitrofurazone dressing
Number of subjects: 36
Study 15126548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg recombinant human TSH (rhTSH)
Number of subjects: 9
Study 15126548 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 9
Study 11431171 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. tiagabine (three times daily)
Number of subjects: 347
Study 11431171 — intervention group
Group type: COMPARATOR
Intervention: b.i.d. tiagabine (twice daily)
Number of subjects: 347
Study 11431171 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. tiagabine
Number of subjects: 347
Study 11431171 — intervention group
Group type: COMPARATOR
Intervention: b.i.d. tiagabine
Number of subjects: 347
Study 9701179 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA-free canola oil blend
Number of subjects: 38
Study 9701179 — intervention group
Group type: COMPARATOR
Intervention: TFA-containing canola oil blend
Number of subjects: 38
Study 9701179 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA-free polyunsaturated oil blend
Number of subjects: 38
Study 9701179 — intervention group
Group type: COMPARATOR
Intervention: TFA-containing polyunsaturated oil blend
Number of subjects: 38
Study 9701179 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 38
Study 1572037 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 150
Study 1572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ST segment depression
Number of subjects: 150
Study 1572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 150
Study 1572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ST segment abnormalities during daily activities
Number of subjects: 150
Study 1572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive VA
Number of subjects: 150
Study 1572037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year follow-up
Number of subjects: 150
Study 2860135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1
Study 2860135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 29272068 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina Sativa Oil (10 g d‐1 ALA)
Number of subjects: 79
Study 29272068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Fish (four fish meals/week)
Number of subjects: 79
Study 29272068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Fish (four fish meals/week)
Number of subjects: 79
Study 29272068 — intervention group
Group type: COMPARATOR
Intervention: Control (limited intakes of fish and sources of ALA)
Number of subjects: 79
Study 26780945 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (Botox)
Number of subjects: 57
Study 26780945 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA (Dysport)
Number of subjects: 57
Study 26780945 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin)
Number of subjects: 57
Study 26780945 — intervention group
Group type: EXPERIMENTAL
Intervention: All neurotoxin groups
Number of subjects: 57
Study 25118597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant sclerostin levels
Number of subjects: 42
Study 25118597 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant sclerostin levels
Number of subjects: 42
Study 25118597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant sclerostin levels and time after transplantation
Number of subjects: 42
Study 23554756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training for 3 months starting 3 days after percutaneous coronary intervention
Number of subjects: 57
Study 23554756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation training)
Number of subjects: 57
Study 19410716 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 1125
Study 19410716 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1125
Study 17064957 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a (180mg/week) plus RBV (800mg/day) for 24 weeks
Number of subjects: 41
Study 17064957 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a (180mg/week) plus RBV (800mg/day) for 24 weeks (n=35)
Number of subjects: 41
Study 17064957 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a plus RBV
Number of subjects: 41
Study 15127083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg lorazepam
Number of subjects: 12
Study 15127083 — intervention group
Group type: COMPARATOR
Intervention: 100 mg caffeine
Number of subjects: 12
Study 15127083 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 12462516 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional shifts directed by central visual symbolic cues with SOA of 300 ms, 700 ms, or 1,100 ms
Number of subjects: 0
Study 12462516 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional shifts directed by central visual symbolic cues
Number of subjects: 0
Study 15512028 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 510
Study 15512028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 510
Study 15512028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium and low-dose aspirin
Number of subjects: 510
Study 15512028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 510
Study 8830066 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 8830066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2195514 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric inhalation device
Number of subjects: 0
Study 2195514 — intervention group
Group type: COMPARATOR
Intervention: Metered-dose aerosols
Number of subjects: 0
Study 761518 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-ladder exercise
Number of subjects: 79
Study 761518 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometry
Number of subjects: 79
Study 31571135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 16
Study 31571135 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 16
Study 28629318 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine oral rinse solution
Number of subjects: 103
Study 28629318 — intervention group
Group type: COMPARATOR
Intervention: Usual oral hygiene care (Control)
Number of subjects: 103
Study 28629318 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Oral Intake Scale (FOIS)-level
Number of subjects: 103
Study 25329436 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated family planning services into HIV care
Number of subjects: 30
Study 25329436 — intervention group
Group type: COMPARATOR
Intervention: Control sites (non-integrated FP services)
Number of subjects: 30
Study 23867539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl
Number of subjects: 56
Study 23867539 — intervention group
Group type: EXPERIMENTAL
Intervention: HES
Number of subjects: 56
Study 21487057 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg intramuscularly for two consecutive days
Number of subjects: 320
Study 21487057 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly for two consecutive days
Number of subjects: 320
Study 19435472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 100
Study 19435472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 16687939 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 15414
Study 15491494 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically based behavioural change programme delivered by telephone
Number of subjects: 365
Study 15491494 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically based behavioural change programme delivered face-to-face in the family home
Number of subjects: 365
Study 15491494 — intervention group
Group type: COMPARATOR
Intervention: Brief written advice (comparison group)
Number of subjects: 365
Study 15491494 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of individual and family activity, psychological mediators of behaviour change, physiological and biochemical correlates, acceptability, and costs
Number of subjects: 365
Study 11387277 — intervention group
Group type: COMPARATOR
Intervention: 100 IU recombinant FSH
Number of subjects: 179
Study 11387277 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU recombinant FSH
Number of subjects: 179
Study 9219211 — intervention group
Group type: EXPERIMENTAL
Intervention: hands on clip-on aero-handlebars (AP)
Number of subjects: 14
Study 8050140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a combination of n‐3 (marine oil) and n‐6 (evening primrose oil) essential fatty acids
Number of subjects: 37
Study 8050140 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 2903876 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (25 mg)
Number of subjects: 33